Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-09-13
2005-09-13
Johannsen, Diana B. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S023200, C536S023500, C536S024310
Reexamination Certificate
active
06942970
ABSTRACT:
The present invention provides methods for diagnosing and treating cancer, and in particular methods for determining the susceptibility of subjects suspected of having breast cancer (or known to have breast cancer) to treatment with topoisomerase II inhibitors. The present invention also provides in situ hybridization probes for specifically detecting topoIIα gene sequences.
REFERENCES:
patent: 5643761 (1997-07-01), Fisher et al.
patent: 5750340 (1998-05-01), Kim et al.
patent: 6070126 (2000-05-01), Kokolus et al.
Tanner, M.M. et al. Topoisomerase IIalpha amplification and deletion predict response to chemotherapy in breast cancer. Proceedings of the American Association for Cancer Research 41:802 (Mar. 2000).
Jarvinen, T.A.H. et al. Amplification and deletion of topoisomerase IIalpha associate with erbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. American Journal of Pathology 156(e):839-847 (Mar. 2000).
Aileen Constans, “No FISHing”, The Scientist, vol. 14, Issue 15 (2000).
Spot-Light™ HER2 DNA Probe, An SPT™ Probe for In Situ Hybridization, Zymed® Laboratories, Inc., Product Information Sheet, distributed beginning in Oct. 1999.
Spot-Light™ CISH Detection Kit, Zymed® Laboratories Inc., Product Information Sheet, distributed beginning in Oct. 1999.
Spot-Light™ Cell Pretreatment Reagent for Enzyme Reagent for Cell Preparations prior to ISH Detection, Zymed® Laboratories Inc., Product Information Sheet, distributed beginning in Oct. 1999.
Spot-Light™ Tissue Pretreatment Kit for Enzyme and Heat Pretreatment of FFPE Tissue prior to ISH, Zymed® Laboratories Inc., Product Information Sheet, distributed beginning in Oct. 1999.
Allred et al.,Mod. Pathol.,11:155-168 [1998].
Kuo et al.,Am. J. Hum. Genet.,49:112-119 (1991).
McNeil, C.,J. Natl. Cancer Inst., 91:100, [1999].
Tetu et al.,Mod. Pathol., 11:823 [1998].
Clahsen et al.,J. Clin. Oncol., 16:470 [1998].
Thor et al.,J. Natl. Cancer Inst., 90:1346 [1998].
Shak. S.,Semin. Oncol., 6:71 [1999].
Jiminez et al.,Mod. Pathol., 13:37 [2000].
Mitchell, M.S.,Semin. Oncol., 26:108 [1999].
Smith et al.,Oncogene, 8:933 (1993).
Murphy et al.,Int. J. Cancer, 64:18-26 (1996).
Hoare et al.,Br. J. Cancer, 75:275 (1997).
Jarvinen, et al.,British Journal of Cancer, 77(12):2267 (1998).
Tanner et al.,Cancer Res., 54:4257 [1994].
Heiskanen et al.,Genomics, 30:31 [1995].
Kellner et al.,J. Hitochem. Cytochem, 45:251 [1997].
Joensuu et al.,J. Clin. Oncol., 16:3720 [1998].
Miller et al.,Cancer, 47:207-214 [1981].
Grancberg, et al.,Am. J. Clin. Pathol., 113:675 [2000].
Davison et al., Technical Advance. Substracted Unique sequence in situ hybridization Experimental And Diagnostic Applications, Am. J. Pathol., 153:1401-1409 (1998).
Jossart et al., A novel multicolor hybridization scheme applied to localization of a transcribed sequence (D 10S 170/H4) and deletion mapping in the thyroid cancer cell line TPC-1. Cytogenet. Cell. Genet., 75:254-257 (1996).
Pauletti et al., Assessment of methods for tissue-based detection of the Her-2
eu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry, J. Clin. Oncology, 18:3651-3664 (2000).
Miyagi et al., Cloning and characterization of an interstitial deletion at chromosome 11p15 in a sporadic breast cancer, Human Molecular Genetics, 1:705-708 (1992).
Isola Jorma
Jarvinen Tero
Shi Zuo-Rong
Tanner Minna
Wu Rina
Johannsen Diana B.
Medlen & Carroll LLP
Zymed Laboratories, Inc.
LandOfFree
Identifying subjects suitable for topoisomerase II inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Identifying subjects suitable for topoisomerase II inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Identifying subjects suitable for topoisomerase II inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397274